Merrill Lynch Resumes Coverage on Genzyme (GENZ) with a Buy
More News related to GENZ
- Notable Analyst Rating Changes 12/03: BAC, BKD, AVB, THC, RIG Upgraded; KIM, GENZ, REG, TCK Downgraded
- Genzyme (GENZ) Reopens Alglucosidase ATAP Enrollment
- Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program
- Collins Stewart Downgrades Genzyme (GENZ) to Hold; Await Additional Execution and Clarity on Troubled Fronts
- Notable Analyst Rating Changes 12/2: AMR/UAUA, RFMD, STI, SAY, KBH, BBT Upgraded; STZ, MTL, BWP, POM Downgraded
Merrill Lynch resumes coverage on Genzyme (Nasdaq: GENZ) with a Buy.
Genzyme Corporation is a biotechnology company. The Company operates in six units.
Related Categories
New CoverageStocks Mentioned
-0.29Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
